The Food and Drug Administration (FDA) last week denied a request by German drug maker Bayer AG to change the label on packages of its aspirin to promote the benefits of regular aspirin therapy to ward off first heart attack or stroke in people who have never had cardiovascular problems. Now the agency is questioning whether the treatment carries any value to those with no heart issues and whether taking a daily aspirin may actually put these individuals at risk for potentially serious side effects. Aspirin therapy is often recommended for people with cardiovascular disease because it reduces the clotting ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.